< Clinical Trials

SHIELD DMD

A Phase II Multicenter, Open-Label Study to Evaluate The Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab In Pediatric Patients With Duchenne Muscular Dystrophy

Study Description:

A study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) age 8 to <18 years old receiving corticosteroid therapy. A subset of participants age 12 to < 18 will be initially treated to assess PK/PD before treating participants below 12 years of age.

Eligibility Criteria:

Inclusion:

  • 8-17 years old
  • Genetic diagnosis of DMD
  • On daily steroids for a year

Exclusion:

  • Severe scoliosis

Clinicaltrials.gov Study Details >

Contact Information: For more information, email Victoria Marren or call 501-364-1921.

Principal Investigator